Clinical Implications of Sarcopenic Obesity in Cancer

被引：124

作者：

Carneiro, Isabella P. ^{[1
]}

Mazurak, Vera C. ^{[1
]}

Prado, Carla M. ^{[1
]}

机构：

[1] Univ Alberta, Dept Agr Food & Nutr Sci, Fac Agr Life & Environm Sci, Li Ka Shing Ctr Hlth Innovat 4 002, Edmonton, AB T6G 2E1, Canada

来源：

CURRENT ONCOLOGY REPORTS | 2016年 / 18卷 / 10期

关键词：

Sarcopenic obesity; Body composition; Cancer; Chemotherapy toxicity; Survival; Morbidity; BODY-MASS INDEX; SKELETAL-MUSCLE DEPLETION; LEAN TISSUE; NEOADJUVANT CHEMOTHERAPY; OVERWEIGHT PATIENTS; PROTEIN-SYNTHESIS; ADIPOSE-TISSUE; CACHEXIA; SURVIVAL; COMPLICATIONS;

D O I：

10.1007/s11912-016-0546-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Sarcopenia has been associated with several negative clinical outcomes in cancer. However, the consequences of sarcopenic obesity, a condition of combined sarcopenia and obesity burden, have been less extensively investigated. The aim of this paper was to review the current evidence on the prevalence and clinical implications of sarcopenic obesity in cancer. A total of 14 studies linking sarcopenic obesity to a clinical outcome in cancer were included. There is considerable inconsistency in methods used to evaluate body composition as well as in the criteria used to define sarcopenic obesity, which limits comparison among studies. Therefore, the prevalence of sarcopenic obesity varied substantially: between 1 and 29 % in studies including individuals from all body mass index categories and between 15 and 36 % for those including obese individuals only. Negative clinical outcomes reported to be associated with sarcopenic obesity included higher risk of dose-limiting toxicity, surgical complications, physical disability, and shorter survival.

引用

页数：13

共 78 条

[1] Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients [J].